Skip To Main Content
Melissa Davey on Muck Rack

Melissa Davey

Melbourne
As seen in: The Guardian Australia, MSN Australia, MSN Canada, MSN India, MSN UK, The Guardian, Yahoo Canada, Yahoo News UK, Yahoo Singapore, MIT Sloan Management Review, Yahoo Finance UK and
Medical Editor of Guardian Australia. Author of 'The Case of George Pell; reckoning with child sexual abuse'. Dancer with The Bluebelles. Fitness Instructor.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Melissa

Contact Melissa, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ads call ovarian cancer a ‘silent killer’. But does urging women to undergo early detection testing do more harm than good?

|
By Melissa Davey
| Inkl
Ovarian cancer is more common in older women with a family history of the disease. Composite: Guardian design/Getty Images “Early detection blood testing” for ovarian cancer “is now available in Australia”, the online ads say, warning that “it’s not just women with a family history” who can be diagnosed. The ad calls the cancer a “silent killer” and says women who wish to be “proactive” can visit a website for early detection.
Open in Who Shared Issue with article?

Life-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved?

|
By Melissa Davey, Tom McIlroy Verified
| MSN Australia Verified
Melissa Davey and Tom McIlroy Australians living with multiple sclerosis will continue receiving cheaper access to life-changing medical treatments, after an expert advisory panel decided to maintain taxpayer subsidies for key drugs. The health minister, Mark Butler, confirmed on Thursday that the drugs – Ocrevus, Kesimpta and Lemtrada – would not be removed from the Pharmaceutical Benefits Scheme, ending uncertainty sparked by their manufacturers, which were pushing the government to pay more.
Open in Who Shared View Duplicates (3) Issue with article?

Life-changing MS drugs to stay on the PBS. So why are others under threat – and how is Trump involved?

|
By Melissa Davey, Tom McIlroy Verified
| Inkl
Butler said he supported the drugs remaining on the PBS because of their clinical benefits. However, the advisory committee has also called for a rapid review of the use of MS drugs, set to be completed before the end of the year, when a final decision will be made. It comes after a number of pharmaceutical companies have pulled drugs – or said they could be withdrawn – from the PBS in recent months.
Open in Who Shared View Duplicates (4) Issue with article?
See all 344 licensed articles (2,851 Total)